Linking oncogenesis and immune system evasion in acquired resistance to EGFR-targeting antibodies Lessons from a preclinical model

Searching for biomarkers that associated with the acquired resistance of malignant cells to epidermal growth factor receptor (EGFR)-targeting monoclonal antibodies is crucial to improve the clinical benefits of these therapeutic agents. We have recently demonstrated that molecular alterations in bot...

Full description

Saved in:
Bibliographic Details
Published inOncoimmunology Vol. 2; no. 12; p. e26904
Main Authors Garrido, Greta, Rabasa, Ailem, Sánchez, Belinda
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 01.12.2013
Landes Bioscience
Subjects
acquired resistance
Author's View
EGFR
MHCI alterations
monoclonal antibodies
MHCI alterations
EGFR
acquired resistance
monoclonal antibodies
Online AccessGet full text

Cover

More Information
Summary:Searching for biomarkers that associated with the acquired resistance of malignant cells to epidermal growth factor receptor (EGFR)-targeting monoclonal antibodies is crucial to improve the clinical benefits of these therapeutic agents. We have recently demonstrated that molecular alterations in both oncogenic and immunological pathways may be responsible for such an insensitivity. Our findings suggest that a combination of targeted anticancer agents and immunomodulatory drugs may be useful for overcoming the acquired resistance of cancer cells to EGFR-specific monoclonal antibodies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2162-4011
2162-402X
2162-402X
DOI:10.4161/onci.26904